NASDAQ$CRBP
Corbus Pharmaceuticals Holding · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Corbus Pharmaceuticals reported financial results for the second quarter of 2021 and provided corporate updates.
Corbus Pharmaceuticals reported revenue from awards and licenses of $137,000 for the second quarter of 2021. Operating expenses decreased by $21.6 million to $16.8 million. The company reported a net loss of $17.1 million, or a net loss per diluted share of $0.15.
- Corbus is expanding its pipeline by licensing two integrin-targeting mAbs.
- The company is on track to progress these assets along with its small molecules into the clinic next year.
- Corbus has a strong financial position with approximately $114M of cash and investments on hand.
- A refundable foreign tax credit of approximately $12.2 million was received subsequent to June 30th.
Headline financials
Revenue & EPS history
Corbus Pharmaceuticals · Revenue · Quarterly
$137K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-1.6%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+8.6%
Avg return
30 days after
30%
14 / 46 earnings
Positive
+23.0%
Q4 2023
Best reaction
-24.2%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.0% | +0.1% | -29.3% | |
| Q4 2025 | +18.6% | +17.5% | +22.8% | |
| Q3 2025 | +6.5% | +8.0% | -6.9% | |
| Q1 2025 | -16.3% | -13.1% | +18.6% | |
| Q4 2024 | -9.1% | -17.4% | -13.4% | |
| Q3 2024 | -0.7% | -5.1% | -19.3% | |
| Q2 2024 | -12.2% | +2.8% | -7.7% | |
| Q1 2024 | +9.2% | +10.7% | +20.0% | |
| Q4 2023 | +23.0% | +14.1% | +4.5% | |
| Q3 2023 | -24.2% | -35.5% | +7.1% | |
| Q2 2023 | -4.7% | +3.9% | +9.5% | |
| Q1 2023 | -8.1% | -2.9% | -8.0% | |
| Q4 2022 | -11.6% | -24.9% | +171.9% | |
| Q3 2022 | -3.8% | +1.5% | -0.8% | |
| Q2 2022 | -4.5% | -3.7% | -25.5% | |
| Q1 2022 | -10.6% | -19.2% | +12.5% | |
| Q4 2021 | +15.4% | +25.5% | +32.7% | |
| Q3 2021 | +5.7% | -3.8% | -28.8% | |
| Q2 2021 | -6.8% | -7.5% | -10.5% | |
| Q1 2021 | +12.1% | +9.4% | +46.3% | |
| Q4 2020 | -6.4% | +0.9% | -25.3% | |
| Q3 2020 | +0.0% | +4.9% | +8.2% | |
| Q2 2020 | -7.6% | -2.7% | +29.4% | |
| Q1 2020 | +3.3% | +4.3% | +11.0% | |
| Q4 2019 | -1.2% | +2.2% | +39.6% | |
| Q3 2019 | -6.4% | -11.0% | +4.7% | |
| Q2 2019 | +3.2% | +7.0% | -4.4% | |
| Q1 2019 | -0.8% | -4.9% | -9.9% | |
| Q4 2018 | +8.1% | +11.1% | +17.1% | |
| Q3 2018 | -13.3% | -16.5% | -9.4% | |
| Q2 2018 | +0.0% | +2.6% | +12.5% | |
| Q1 2018 | -14.5% | -1.6% | -10.2% | |
| Q4 2017 | -4.9% | +0.0% | -12.7% | |
| Q3 2017 | +2.9% | +0.0% | +10.2% | |
| Q2 2017 | -4.1% | -0.8% | +10.7% | |
| Q1 2017 | -4.0% | +1.6% | +2.4% | |
| Q4 2016 | +1.6% | +4.4% | -20.9% | |
| Q3 2016 | -9.3% | +26.4% | +20.9% | |
| Q2 2016 | -1.0% | +5.5% | +67.2% | |
| Q1 2016 | -2.5% | — | — | |
| Q4 2015 | -3.8% | — | — | |
| Q3 2015 | -1.8% | — | — | |
| Q2 2015 | -6.1% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | -0.5% | — | — | |
| Q3 2014 | +16.7% | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro